TP53 and cancer: It is also important to note that, despite its increasing applications in studying cancer vulnerability, multiple recent studies have shown that CRISPR/Cas9-based technology significantly alters p53-mediated functions and signaling pathways (Haapaniemi et al., 2018; Enache et al., 2020; Jiang et al., 2021; Sinha et al., 2021).